Comparative Pharmacology
Head-to-head clinical analysis: AJOVY versus UBROGEPANT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AJOVY versus UBROGEPANT.
AJOVY vs UBROGEPANT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ajovy (fremanezumab) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the CGRP receptor, thereby inhibiting CGRP-mediated neurogenic vasodilation and pain transmission in trigeminal sensory neurons.
Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It binds to CGRP receptors, blocking the vasodilatory and pro-inflammatory effects of CGRP, thereby aborting migraine attacks without causing vasoconstriction.
AJOVY (fremanezumab-vfrm) is administered subcutaneously at a dose of 675 mg once every 3 months (quarterly) or 225 mg once monthly. The injection volume is 1.5 mL for the 225 mg dose and 4.5 mL for the 675 mg dose, administered as three separate injections of 225 mg each.
50 mg or 100 mg orally once daily as needed for acute treatment of migraine attacks; maximum daily dose: 200 mg. Not for prophylactic use.
None Documented
None Documented
Terminal elimination half-life is 31 days (range 23-37 days). This long half-life supports monthly subcutaneous dosing.
Terminal elimination half-life is ~5-7 hours, supporting twice-daily dosing for migraine prevention.
Renal excretion of intact antibody is minimal; metabolized via catabolism to peptides and amino acids. Approximately 100% of elimination is via intracellular degradation (proteolysis) and biliary excretion of metabolites, with negligible renal excretion.
Primarily eliminated via biliary/fecal excretion (approximately 70% of dose recovered in feces) with ~30% renal excretion (mostly as unchanged drug).
Category C
Category C
CGRP Antagonist
CGRP Antagonist